Compare · GCTK vs SYK
GCTK vs SYK
Side-by-side comparison of GlucoTrack Inc. (GCTK) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GCTK and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $119.75B, about 42502.2x GCTK ($2.8M).
- Over the past year, GCTK is down 95.6% and SYK is down 20.0% - SYK leads by 75.6 points.
- GCTK has been more active in the news (13 items in the past 4 weeks vs 8 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 0 for GCTK).
- Company
- GlucoTrack Inc.
- Stryker Corporation
- Price
- $3.53-5.11%
- $312.12-1.65%
- Market cap
- $2.8M
- $119.75B
- 1M return
- -61.27%
- -7.00%
- 1Y return
- -95.55%
- -19.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 13
- 8
- Recent ratings
- 0
- 25
GlucoTrack Inc.
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest GCTK
- Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business
- GlucoTrack Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 425 filed by GlucoTrack Inc.
- Amendment: GlucoTrack Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets
- GlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Glucotrack, Inc. Announces Reverse Stock Split
- Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100
- SEC Form DEFA14A filed by GlucoTrack Inc.
- Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia
- GlucoTrack Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest SYK
- Director Brainerd Mary K bought $26,736 worth of shares (131 units at $204.09) (SEC Form 4)
- Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
- Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
- Stryker to participate in the 2026 Wells Fargo Healthcare Conference
- Group President Crotty Dylan Bram sold $144,915 worth of shares (441 units at $328.61) (SEC Form 4)
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend